HPV vaccine and screening study for women in Rwanda
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests giving the HPV vaccine along with HPV screening to quickly reduce HPV infection and cervical cancer. It is for women aged 23-29 in Rwanda who choose to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 23 and 29 years old.
- You have not opted out of the cervical cancer screening program.
- You agree to take part in the study.
- You are not pregnant.
- You have not had a severe allergic reaction to the HPV vaccine or its ingredients (like aluminum or yeast).
- You have not had a total hysterectomy (surgery to remove the uterus and cervix).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at giving the HPV vaccine (Gardasil 9) to women while they go through Sweden’s routine HPV screening. It helps researchers understand how vaccine use alongside screening affects HPV infection and cervical cancer prevention.
This trial tests a 9-type HPV vaccine to see how well it works, how it helps the body build protection, and whether it’s safe. It’s for healthy Chinese women who have not had HPV vaccination before and meet specific health and timing requirements.
This trial tests how well the HPV vaccine triggers immune memory in women who may have been exposed to HPV. It could help protect against future HPV infections and related cancers.
This study tests if a single dose of the HPV vaccine (Gardasil 9) can lower the amount of HPV virus in women who already have the virus, potentially reducing how easily it spreads. It will help us learn if vaccination can protect partners and communities.
This study tests whether using one or two screening tools (HPV test or VIA) is better at finding cervical precancer in women with HIV. It may help improve screening and treatment for cervical cancer.
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.